Literature DB >> 24065331

Causes of death and characteristics of decedents with viral hepatitis, United States, 2010.

Kathleen N Ly1, Jian Xing, R Monina Klevens, Ruth B Jiles, Scott D Holmberg.   

Abstract

BACKGROUND: Previous research indicates that the mortality burden from viral hepatitis is growing, particularly among middle-aged persons. To monitor progress toward prevention goals, it is important to continue to document characteristics and comortalities of these deaths. This study sought to examine demographic characteristics and the most frequent causes of death among decedents with a viral hepatitis-related death.
METHODS: A cross-sectional study was performed on approximately 2.4 million death records from 2010. We calculated mortality rates for decedents with and without hepatitis A, B, and C virus (HAV, HBV, and HCV) and relative risks for the most frequently cited conditions in decedents with and without HBV and HCV.
RESULTS: In 2010, there were 18 473 (0.7%) deaths with HAV, HBV, and HCV listed among causes of death, disproportionately in those aged 45-64 years. Among the 10 frequent causes of death, decedents listing HBV or HCV died, on average, 22-23 years earlier than decedents not listing these infections. HBV- and HCV-infected decedents aged 45-64 years had an increased risk of having the following conditions reported than decedents without these infections: cancer of liver and intrahepatic bile duct; fibrosis, cirrhosis, and other liver diseases; alcohol-related liver disease; gastrointestinal hemorrhage; human immunodeficiency infection; acute and unspecified renal failure; and septicemia (HCV only).
CONCLUSIONS: Decedents with other causes of death that include HBV or HCV died 22-23 years earlier than decedents not listing these infections. These data suggest and support the need for prevention, early identification, and treatment of HBV and HCV.

Entities:  

Keywords:  causes of death; death certificates; mortality; viral hepatitis

Mesh:

Year:  2013        PMID: 24065331     DOI: 10.1093/cid/cit642

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  32 in total

1.  Hepatitis C-Related Mortality Among American Indian/Alaska Native Persons in the Northwestern United States, 2006-2012.

Authors:  Sarah M Hatcher; Sujata Joshi; Byron F Robinson; Thomas Weiser
Journal:  Public Health Rep       Date:  2019-11-25       Impact factor: 2.792

2.  Results of Hepatitis C Birth-Cohort Testing and Linkage to Care in Selected U.S. Sites, 2012-2014.

Authors:  Rajiv C Patel; Claudia Vellozzi; Bryce D Smith
Journal:  Public Health Rep       Date:  2016 May-Jun       Impact factor: 2.792

3.  Estimating the Number of Patients Infected With Chronic HCV in the United States Who Meet Highest or High-Priority Treatment Criteria.

Authors:  Fujie Xu; Andrew J Leidner; Xin Tong; Scott D Holmberg
Journal:  Am J Public Health       Date:  2015-05-14       Impact factor: 9.308

Review 4.  Vaccination in the elderly: what can be recommended?

Authors:  Pierre-Olivier Lang; Richard Aspinall
Journal:  Drugs Aging       Date:  2014-08       Impact factor: 3.923

5.  "Know More Hepatitis:" CDC's National Education Campaign to Increase Hepatitis C Testing Among People Born Between 1945 and 1965.

Authors:  Cynthia Jorgensen; C Amanda Carnes; Alycia Downs
Journal:  Public Health Rep       Date:  2016 May-Jun       Impact factor: 2.792

6.  Overt gastrointestinal bleeding following haploidentical haematopoietic stem cell transplantation: incidence, outcomes and predictive models.

Authors:  Xueyan Sun; Yan Su; Xiao Liu; Yuanyuan Zhang; Yun He; Wei Han; Qi Chen; Huan Chen; Yu Wang; Yifei Cheng; Fengqi Liu; Fengrong Wang; Yao Chen; Gaochao Zhang; Xiaodong Mo; Haixia Fu; Yuhong Chen; Jingzhi Wang; Xiaolu Zhu; Lanping Xu; Kaiyan Liu; Xiaojun Huang; Xiaohui Zhang
Journal:  Bone Marrow Transplant       Date:  2021-01-07       Impact factor: 5.483

7.  Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease.

Authors:  Andrew J Leidner; Harrell W Chesson; Philip R Spradling; Scott D Holmberg
Journal:  Appl Health Econ Health Policy       Date:  2017-02       Impact factor: 2.561

8.  Hepatitis C virus testing for case identification in persons born during 1945-1965: Results from three randomized controlled trials.

Authors:  Anthony K Yartel; David B Rein; Kimberly Ann Brown; Katherine Krauskopf; Omar I Massoud; Cynthia Jordan; Natalie Kil; Alex D Federman; David R Nerenz; Joanne E Brady; Danielle L Kruger; Bryce D Smith
Journal:  Hepatology       Date:  2018-01-02       Impact factor: 17.425

9.  Viral hepatitis among drug users in methadone maintenance: associated factors, vaccination outcomes, and interventions.

Authors:  David C Perlman; Ashly E Jordan; Courtney McKnight; Christopher Young; Kevin L Delucchi; James L Sorensen; Don C Des Jarlais; Carmen L Masson
Journal:  J Addict Dis       Date:  2014

10.  Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.

Authors:  A Blythe Ryerson; Christie R Eheman; Sean F Altekruse; John W Ward; Ahmedin Jemal; Recinda L Sherman; S Jane Henley; Deborah Holtzman; Andrew Lake; Anne-Michelle Noone; Robert N Anderson; Jiemin Ma; Kathleen N Ly; Kathleen A Cronin; Lynne Penberthy; Betsy A Kohler
Journal:  Cancer       Date:  2016-03-09       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.